Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality

BMC Clinical Pharmacology

Billy Ngasala²  Omary Minzi¹  Vicent P Manyanga¹ 

[1]Unit of Pharmacology and Therapeutics, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania

[2]Department of Parasitology, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania

关键词: Co-trimoxazole prophylaxis;    Anaemia;    Pregnancy;    Malaria;    HIV;   

Others  :  860336
DOI  :  10.1186/2050-6511-15-24

 received in 2013-11-16, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

HIV-infected pregnant women are particularly more susceptible to the deleterious effects of malaria infection particularly anaemia. In order to prevent opportunistic infections and malaria, a policy of daily co-trimoxazole prophylaxis without the standard Suphadoxine-Pyrimethamine intermittent preventive treatment (SP-IPT) was introduced to all HIV infected pregnant women in the year 2011. However, there is limited information about the effectiveness of this policy.

Methods

This was a cross sectional study conducted among HIV-infected pregnant women receiving co-trimoxazole prophylaxis in eight public health facilities in Kinondoni Municipality from February to April 2013. Blood was tested for malaria infection and anaemia (haemoglobin <11 g/dl). Data were collected on the adherence to co-trimoxazole prophylaxis and other risk factors for malaria infection and anaemia. Pearson chi-square test, Fischer’s exact test and multivariate logistic regression were used in the statistical analysis.

Results

This study enrolled 420 HIV infected pregnant women. The prevalence of malaria infection was 4.5%, while that of anaemia was 54%. The proportion of subjects with poor adherence to co-trimoxazole was 50.5%. As compared to HIV infected pregnant women with good adherence to co-trimoxazole prophylaxis, the poor adherents were more likely to have a malaria infection (Adjusted Odds Ratio, AOR = 6.81, 95% CI = 1.35-34.43, P = 0.02) or anaemia (AOR = 1.75, 95% CI = 1.03-2.98, P = 0.039). Other risk factors associated with anaemia were advanced WHO clinical stages, current malaria infection and history of episodes of malaria illness during the index pregnancy.

Conclusion

The prevalence of malaria was low; however, a significant proportion of subjects had anaemia. Good adherence to co-trimoxazole prophylaxis was associated with reduction of both malaria infection and anaemia among HIV infected pregnant women.

【 授权许可】

   
2014 Manyanga et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Steketee R, Wirima J, Bloland P, Chilima B, Mermin J: Impairment of a pregnant woman’s acquired ability to limit Plasmodium falciparum by infection with Human Immunodeficiency Virus type-1. Am J Trop Med Hyg 1996, 55(1):42-49.
• [2]Ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, Van Eijk AM, Rogerson SJ, Steketee RW: The burden of co-infection with Human Immunodeficiency Virus type 1 and malaria in pregnant women in Sub-Saharan Africa. Am J Trop Med Hyg 2004, 71(2):41-54.
• [3]Mount AM, Mwapasa V, Elliott SR, Beeson JG: Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004, 363(9424):1860-1867.
• [4]Ned RM, Moore JM, Chaisavaneeykorn S, Udhayakumar V: Modulation of immune responses during HIV–malaria co-infection in pregnancy. Trends Parasitol 2005, 21(6):284-291.
• [5]World Health Organization: Guideline on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings. Recommendations for a public health approach. Geneva; 2006.
• [6]Ministry of Health and Social Welfare: Tanzania National Guideline for Prevention of Mother-to-child Transmission of HIV/AIDS. Dar Es Salaam; 2011.
• [7]De Castro MC, Yamagata Y, Mtasiwa D, Tanner M, Utzinger J, Keiser J, Singer BH: Integrated urban malaria control: a case study in Dar Es Salaam. Am J Trop Med Hyg 2004, 71(Suppl 2):103-117.
• [8]Omo-Aghoja LO, Abe E, Feyi-Waboso P, Okonofua FE: The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings. Acta Obstet Gynecol 2008, 87(7):693-696.
• [9]Uneke CJ: Diagnosis of Plasmoduim falciparum malaria in pregnancy in Sub-Saharan Africa: the challenges and public health implications. J Parasitol Res 2008, 102:333-342.
• [10]Leke RFG, Djokam RR, Mbu R, Leke RJ, Fogako J, Megnekou R, Matenou S, Sama G, Zhou Y, Cadigan T, Parra M, Taylor DW: Detection of the Plasmodium falciparum antigen histidine-rich protein 2 in blood of pregnant women : implications for diagnosing placental malaria. J Clin Microbiol 1999, 37(9):2992-2996.
• [11]The Municipal Medical Officer of Health: Kinondoni municipality profile. Dar Es Salaam; 2008.
• [12]Newman PM, Wanzira H, Tumwine G, Arinaitwe E, Waldman S, Achan J, Havlir D, Rosenthal PJ, Dorsey G, Clark TD, Cohan D: Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J 2009, 8:254. BioMed Central Full Text
• [13]Morisky D, Green L, Levine D: Concurrent and predictive validity of a self-reported measure of medication adherence. J Med Care 1986, 24(1):67-74.
• [14]Morisky DE, Ang A, Krousel-wood M: Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertesion 2009, 10(5):348-354.
• [15]World Health Organization: Prevention and management of severe anaemia in pregnancy. Geneva; 1993.
• [16]World Health Organization: WHO, case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva; 2007.
• [17]Kapito-tembo A, Hensbroek van B, Phiri K, Fitzgerald M, Meshnick SR, Mwapasa V: Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with Or without Sulfadoxine-Pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011, 203:464-472.
• [18]World Health Organization: Malaria rapid diagnostic tests: Test of Performance. Geneva; 2008.
• [19]World Health Organization: A strategic framework for malaria prevention and control during pregnancy in the African region. Geneva; 2004.
• [20]Renggli S, Mandike R, Kramer K, Patrick F, Brown NJ, McElroy PD, Rimisho W, Msengwa A, Mnzava A, Nathan R, Ntunge R, Mgullo R, Lweikiza J, Lengeler C: Design, implementation and evaluation of a national campaign to deliver 18 million free long-lasting insecticidal nets to uncovered sleeping spaces in Tanzania. Malar J 2013, 12:1. BioMed Central Full Text
• [21]Maxwell CA, Msuya E, Sudi M, Njunwa KJ, Carneiro IA, Curtis CF: Effect of community-wide use of insecticide-treated nets for 3–4 years on malarial morbidity in Tanzania. J Trop Med Int Heal 2002, 7(12):1003-1008.
• [22]West PA, Protopopoff N, Rowland M, Cumming E, Rand A, Drakeley C, Wright A, Kivaju Z, Kirby MJ, Mosha FW, Kisinza W, Kleinschmidt I: Malaria risk factors in North West Tanzania: the effect of spraying, nets and wealth. PLoS One 2013, 8(6):e65787.
• [23]Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P: Effect of co-trimoxazole prophylaxis, antiretroviral therapy and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda : a prospective cohort study. Lancet 2006, 367:1256-1261.
• [24]Tanzania National AIDS Control Program: National Guideline for the Management of HIV/AIDS. Dar Es Salaam; 2012.
• [25]Finkelstein JL, Mehta S, Duggan CP, Spiegelman D, Aboud S, Kupka R, Msamanga GI, Fawzi WW: Predictors of anaemia and iron deficiency in HIV-infected pregnant women in Tanzania: a potential role for vitamin D and parasitic infections. Public Health Nutr 2013, 15(5):928-937.
• [26]Mehta S, Manji KP, Young AM, Brown ER, Chasela C, Taha E, Read JS, Golnberg RL, Fawzi WW: Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr 2008, 87(6):1639-1649.
• [27]Uneke CJ, Duhlinska DD, Igbinedion EB: Immunodeficiency Virus infection and anaemia during pregnancy in eastern Nigeria: The public health implication. Infect Dis Clin Pract 2007, 15(4):239-244.
• [28]Nkhoma ET, Kalilani-phiri L, Mwapasa V, Rogerson SJ, Meshnick SR: Effect of HIV infection and Plasmodium falciparum parasitemia on pregnancy outcomes in Malawi. Am J Trop Med Hyg 2012, 87(1):29-34.
• [29]Walker AS, Mulenga V, Ford D, Kabamba D, Sinyinza F, Kankasa C, Chintu C, Gibb DM: The impact of daily co-trimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 2007, 44:1361-1367.
• [30]Weiss G, Goodnough LT: Anaemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
• [31]Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, Sullivan BPS: Epidemiology of anaemia in Human Immunodeficiency Virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
• [32]Ziske J, Kunz A, Sewangi J, Lau I, Dugange F, Hauser A, Kirschner , Harms G, Theuring S: Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child transmission of HIV in Tanzania. PLoS One 2013, 8(2):e55633.
• [33]World Health Organization: Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Recommendations for a public health approach. Geneva; 2010.
• [34]Sharma SK: Zidovudine-induced anaemia in HIV/AIDS. Indian J Med Res 2010, 132:359-361.
• [35]Sinha G, Choi TJ, Nayak U, Gupta A, Nair S, Gupte N, Bulakh PM, Satry J, Deshmukh SD, Khandekar MM, Kulkarni V, Bhosele RA, Bharuche KE, Phadke MA, Kshirsagar AS, Bolinger RC: Clinically significant anaemia in HIV-infected pregnant women in India is not a major barrier to Zidovudine use for prevention of maternal-to-child transmission. J Acquir Immune Defic Syndr 2007, 45:210-217.